Canada markets open in 7 hours 14 minutes
  • S&P/TSX

    19,779.97
    -11.63 (-0.06%)
     
  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     
  • DOW

    33,963.84
    -106.56 (-0.31%)
     
  • CAD/USD

    0.7416
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    90.29
    +0.26 (+0.29%)
     
  • Bitcoin CAD

    35,126.33
    -689.71 (-1.93%)
     
  • CMC Crypto 200

    557.11
    -10.94 (-1.93%)
     
  • GOLD FUTURES

    1,940.60
    -5.00 (-0.26%)
     
  • RUSSELL 2000

    1,776.50
    -5.33 (-0.30%)
     
  • 10-Yr Bond

    4.4380
    0.0000 (0.00%)
     
  • NASDAQ futures

    14,907.75
    +38.25 (+0.26%)
     
  • VOLATILITY

    17.20
    -0.34 (-1.94%)
     
  • FTSE

    7,683.91
    +5.29 (+0.07%)
     
  • NIKKEI 225

    32,683.19
    +280.78 (+0.87%)
     
  • CAD/EUR

    0.6963
    -0.0002 (-0.03%)
     

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

Clearside Biomedical, Inc.
Clearside Biomedical, Inc.

ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

Registration for the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. To participate via telephone, please register in advance using the link provided in the event listing. The Company suggests participants log in 15 minutes in advance of the event.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2 clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.